Teva Pharmaceutical Industries Ltd.’s ability to delay generic competition for its Copaxone (glatiramer acetate) 40mg dosage will depend on favorable court rulings now that the US Patent Office’s Patent Trial and Appeal Board once again knocked out three patents covering the three-times-a-week regimen.
In August, the Board issued a pair of final written decisions on inter partes review (IPR) petitions challenging two patents...





